ZyVersa is a clinical stage specialty biopharmaceutical company leveraging advanced proprietary technologies to develop first-in-class drugs for patients with inflammatory or kidney diseases with high unmet medical needs. We are well positioned in the rapidly emerging inflammasome space with a highly differentiated inflammasome inhibitor (IC 100), and in kidney disease with a novel phase 2a-ready cholesterol efflux mediator (VAR 200). Lead products in each therapeutic area offer a “pipeline within a product,” with potential for numerous indications. The total accessible market is over $70 billion.1,2
IC 100 is a novel inflammasome inhibitor targeting ASC. By targeting ASC, IC 100 inhibits 12 or more types of inflammasomes rather than just one (e.g. NLRP3) to treat a broad range of indications. IC 100 blocks intracellular initiation of the inflammatory cascade and extracellular perpetuation of damaging inflammation that is pathogenic in anti-inflammatory diseases.
VAR 200 is 2-hydroxypropyl-beta-cyclodextrin (2HPβCD), a cholesterol efflux mediator demonstrated in preclinical studies to promote cholesterol removal from podocytes, a component of the kidney's filtering system, slowing progression of podocyte injury and renal disease. VAR 200 is in development for focal segmental glomerulosclerosis (FSGS), a rare kidney disease. ZyVersa’s accomplished leadership team has deep pharmaceutical experience and a successful track record in R&D, commercialization, licensing, M&A, raising capital, and taking companies public. A key focus is assuring that our development efforts serve the needs of all our stakeholders: patients, health care providers, payors, and our investors.
- Credence Research, Inc. Anti-inflammatory Therapeutics Market - Growth, Future Prospects and Competitive Analysis, 2018-2026
- Global Chronic Kidney Disease (CKD) Drugs Market to 2025. Research and Markets, September 2017